

|                    |                      |                 |              |
|--------------------|----------------------|-----------------|--------------|
| <b>POLICY NAME</b> | Agamree (vamorolone) | <b>POLICY #</b> | <b>3258P</b> |
|--------------------|----------------------|-----------------|--------------|

## Criteria

### Coverage Criteria

- ☐ **1.1** Diagnosis of Duchenne Muscular Dystrophy confirmed by one of the following:
  - Genetic testing documenting a mutation in the dystrophin (DMD) gene
  - Muscle biopsy documenting lack of muscle dystrophin
- ☐ **1.2** Age 2 years or older
- ☐ **1.3** Prescribed by or in consultation with a physician who specializes in the treatment of Duchenne Muscular Dystrophy (DMD) and/or neuromuscular disorders
- ☐ **1.4** Patient is currently ambulatory (able to walk independently)
- ☐ **1.5** Documented trial of prednisone for 6 months and documentation that the member experienced at least one of the following significant intolerable adverse effects (AE)
  - Cushingoid appearance
  - Central (truncal) obesity
  - Undesirable weight gain defined as a 10% of body weight gain increase over a 6-month period
  - Diabetes and/or hypertension that is difficult to manage
  - Severe behavioral AE that would require a prednisone dose reduction
  - Clinically significant growth stunting as evidenced by decline in mean height percentile from baseline, decrease in growth velocity or decrease in serum bone formation biomarkers
- ☐ **1.6** Documented trial and failure, intolerance or contraindication to generic deflazacort
- ☐ **1.7** Documentation of a baseline motor milestone score from one of the following assessments:
  - 6-minute walk test (6MWT)
  - Time to stand test (TTSTAND)
  - Time to run/walk test (TTRW)